Technical Analysis for RAC - Race Oncology Ltd  

Grade Last Price % Change Price Change
D 1.360 -6.21% -0.090
RAC closed unchanged on Monday, November 18, 2024, on 1.85 times normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
Earnings due: Nov 26
*** please verify all earnings dates ***
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Hammer Candlestick Bullish -6.21%
Lizard Bullish Bullish Day Trade Setup -6.21%
Doji - Bullish? Reversal -6.21%
Lower Bollinger Band Touch Weakness -6.21%
Oversold Stochastic Weakness -6.21%
Oversold Stochastic Weakness -6.21%
200 DMA Resistance Bearish -4.23%
MACD Bearish Signal Line Cross Bearish -4.23%
Stochastic Reached Oversold Weakness -4.23%
Gapped Up Strength -4.23%

   Recent Intraday Alerts

Alert Time
2x Volume Pace about 3 hours ago
Fell Below Previous Day's Low about 3 hours ago
Down 1 ATR about 3 hours ago
Down 5% about 3 hours ago
Fell Below Lower Bollinger Band about 3 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Race Oncology Ltd   Description

Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Cancer Drugs Clinical Medicine Cancers Therapy Oncology Chemotherapy Isan Leukemia

Is RAC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.09
52 Week Low 0.64
Average Volume 100,485
200-Day Moving Average 1.487
50-Day Moving Average 1.594
20-Day Moving Average 1.489
10-Day Moving Average 1.510
Average True Range 0.073
RSI (14) 43.18
ADX 19.21
+DI 13.915
-DI 27.878
Chandelier Exit (Long, 3 ATRs) 1.425
Chandelier Exit (Short, 3 ATRs) 1.570
Upper Bollinger Bands 1.603
Lower Bollinger Band 1.376
Percent B (%b) 0.33
BandWidth 15.229
MACD Line -0.032
MACD Signal Line -0.029
MACD Histogram -0.0031
Fundamentals Value
Market Cap 185.83 Million
Num Shares 128 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -31.52
Price-to-Sales 0.00
Price-to-Book 48.43
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.600
Resistance 3 (R3) 1.583 1.517 1.575
Resistance 2 (R2) 1.517 1.478 1.525 1.567
Resistance 1 (R1) 1.483 1.455 1.500 1.500 1.558
Pivot Point 1.417 1.417 1.425 1.425 1.417
Support 1 (S1) 1.383 1.378 1.400 1.400 1.342
Support 2 (S2) 1.317 1.355 1.325 1.333
Support 3 (S3) 1.283 1.317 1.325
Support 4 (S4) 1.300